Form 4: Sensei Biotherapeutics CEO Reports Stock Conversion

CEO Anand Kiran Parikh converted Series B Preferred Stock into 761,428 shares of common stock following a merger.

Summary

• Anand Kiran Parikh, President and CEO of Sensei Biotherapeutics, Inc., reported the conversion of Series B Preferred Stock into common stock.
• The transaction involved the conversion of 761.428 shares of Series B Preferred Stock into 761,428 shares of common stock.
• The conversion occurred on June 15, 2026, following the completion of a merger involving Faeth Therapeutics, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting a routine equity conversion following a previously announced merger.

Positives

• The CEO has increased his direct ownership of common stock, signaling alignment with shareholder interests.

Negatives

• None identified in this filing.

Risks

• The conversion is subject to conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing instead on the reporting of a specific ownership change.

Industry Context

StockSavvy.ai notes that this filing reflects post-merger integration activities within the biotechnology sector, where executive equity structures are often adjusted following corporate acquisitions.

Comparison to Industry Standards

• The conversion of preferred stock to common stock following a merger is a standard corporate governance procedure in the biotech industry.
• The reporting timeline adheres to SEC requirements for Section 16(a) disclosures.

Stakeholder Impact

• Shareholders should note the change in the CEO's equity composition from preferred to common stock.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Sensei Biotherapeutics, FTH, Form 4, Insider Trading, Stock Conversion, Merger